Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 2/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9724931 | 0.77 | TSHR (0.45) | LMNAGAAL3MBTL1GRM2 | |
| Bromide SCHEMBL3923746 | 0.76 | TSHR (0.44) | LMNAGAAL3MBTL1GRM2 | |
| SCHEMBL6415820 | 0.75 | LMNA (0.57) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL6360177 | 0.74 | ALDH1A1 (0.53) | CHRNB2CHRNA4LMNAGAAMAPT | |
| SCHEMBL7508741 | 0.74 | CHRNA1 (0.55) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL6358757 | 0.73 | LMNA (0.55) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL7504331 | 0.73 | CHRNB2 (1.00) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL8598824 | 0.71 | LMNA (0.50) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL6323492 | 0.69 | CHRNB2 (0.65) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA | |
| SCHEMBL7507181 | 0.69 | CHRNA1 (0.52) | CHRNA1CHRNA7CHRNB2CHRNA4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | claimed |
| EP-0857725-B1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER (US) | 2001-07-25 | — | — | EP | claimed |
| US-6020335-A | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC (US) | 2000-02-01 | — | — | US | claimed |
| EP-0857725-A1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-08-12 | — | — | EP | claimed |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1439836-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | Pfizer Products Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | disclosed |
| WO-2003037329-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-0857725-B1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6020335-A | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0857725-A1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA7 | CHRNA1 2/4885CHRNA7 3/4885CHRNB2 18/4885 |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA2 | CHRNA1 2/4885CHRNA7 5/4885CHRNB2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.